search
Back to results

Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Combination Versus Insulin Glargine Alone on Top of Metformin in Type 2 Diabetic Patients

Primary Purpose

Type 2 Diabetes Mellitus

Status
Completed
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
Insulin glargine /lixisenatide Fixed Ratio Combination
Insulin glargine
Metformin (Background drug)
Sponsored by
Sanofi
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type 2 Diabetes Mellitus

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion criteria:

  • Participants with type 2 diabetes mellitus diagnosed for at least 1 year.
  • Metformin treatment at a stable dose of at least 1.5 g/day for at least 3 months prior to screening.

Exclusion criteria:

  • Age < legal age of adulthood (18 years).
  • Screening HbA1c <7% or >10%.
  • Screening FPG >250 mg/dL (>13.9 mmol/L).
  • Pregnancy or lactation, women of childbearing potential with no effective contraceptive method.
  • Type 1 diabetes mellitus.
  • Treatment with glucose-lowering agent(s) other than metformin in a period of 3 months prior to screening.
  • Use of insulin within the last 6 months.
  • Previous use of insulin, except for episode(s) of short-term treatment (≤15 consecutive days) due to intercurrent illness.
  • Amylase and/or lipase >3 times the upper limit of the normal laboratory range (ULN) at screening.
  • Calcitonin ≥20 pg/ml (5.9 pmol/l) at screening.
  • Alanine Transferase (ALT) >3 ULN at screening.
  • History of unexplained pancreatitis, chronic pancreatitis, pancreatectomy.
  • Personal or immediate family history of medullary thyroid cancer (MTC) or genetic conditions that predisposes to MTC (e.g. multiple endocrine neoplasia syndromes).
  • Uncontrolled or inadequately controlled hypertension at the time of screening with a resting supine systolic or diastolic blood pressure >180 mmHg or >110 mmHg, respectively.
  • Within the last 6 months prior to screening: history of heart failure requiring hospitalization, myocardial infarction, or stroke. Planned coronary, carotid or peripheral artery revascularisation procedures.
  • Body Mass Index (BMI) ≤20 or >40 kg/m^2.
  • Any previous treatment with lixisenatide

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Sites / Locations

  • Investigational Site Number 840408
  • Investigational Site Number 840412
  • Investigational Site Number 840401
  • Investigational Site Number 840417
  • Investigational Site Number 840403
  • Investigational Site Number 840404
  • Investigational Site Number 840405
  • Investigational Site Number 840411
  • Investigational Site Number 840415
  • Investigational Site Number 840402
  • Investigational Site Number 840407
  • Investigational Site Number 840413
  • Investigational Site Number 840410
  • Investigational Site Number 840414
  • Investigational Site Number 152404
  • Investigational Site Number 152405
  • Investigational Site Number 152403
  • Investigational Site Number 152401
  • Investigational Site Number 152402
  • Investigational Site Number 203403
  • Investigational Site Number 203401
  • Investigational Site Number 203402
  • Investigational Site Number 203405
  • Investigational Site Number 208401
  • Investigational Site Number 208404
  • Investigational Site Number 208402
  • Investigational Site Number 208403
  • Investigational Site Number 250402
  • Investigational Site Number 250404
  • Investigational Site Number 250401
  • Investigational Site Number 276401
  • Investigational Site Number 276402
  • Investigational Site Number 276403
  • Investigational Site Number 348401
  • Investigational Site Number 348405
  • Investigational Site Number 348406
  • Investigational Site Number 348404
  • Investigational Site Number 348402
  • Investigational Site Number 348403
  • Investigational Site Number 440401
  • Investigational Site Number 440402
  • Investigational Site Number 440403
  • Investigational Site Number 440404
  • Investigational Site Number 484404
  • Investigational Site Number 484401
  • Investigational Site Number 484405
  • Investigational Site Number 484402
  • Investigational Site Number 484403
  • Investigational Site Number 616405
  • Investigational Site Number 616406
  • Investigational Site Number 616403
  • Investigational Site Number 616407
  • Investigational Site Number 616404
  • Investigational Site Number 616402
  • Investigational Site Number 616401
  • Investigational Site Number 642402
  • Investigational Site Number 642403
  • Investigational Site Number 642405
  • Investigational Site Number 642401
  • Investigational Site Number 642406
  • Investigational Site Number 642404
  • Investigational Site Number 703402
  • Investigational Site Number 703403
  • Investigational Site Number 703406
  • Investigational Site Number 703404
  • Investigational Site Number 703405
  • Investigational Site Number 703401
  • Investigational Site Number 752402
  • Investigational Site Number 752401
  • Investigational Site Number 752403

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Insulin glargine/Lixisenatide Fixed Ratio Combination (FRC)

Insulin glargine

Arm Description

FRC injected once daily (QD) for 24 weeks. Dose individually adjusted.

Insulin glargine QD for 24 weeks. Dose individually adjusted.

Outcomes

Primary Outcome Measures

Change in HbA1c From Baseline to Week 24
Change in HbA1c was calculated by subtracting baseline value from Week 24 value. Missing data was imputed using last observation carried forward (LOCF). On-treatment period for this efficacy variable was defined as the time from the first dose of study drug till before the introduction of rescue medication and up to 14 days after the last injection of investigational medicinal product (IMP).

Secondary Outcome Measures

Change in 2-hour Postprandial Plasma Glucose (PPG) From Baseline to Week 24
The 2-hour PPG test measured blood glucose 2 hours after eating a standardized meal. Change in PPG was calculated by subtracting baseline value from Week 24 value. Missing data was imputed using LOCF. On-treatment period for this efficacy variable was defined as the time from the first dose of study drug till before the introduction of rescue medication and up to the date of last injection of IMP.
Change in 2-hour Plasma Glucose Excursion From Baseline to Week 24
2-hour plasma glucose excursion = 2-hour PPG minus plasma glucose value obtained 30 minutes prior to the start of the meal and before IMP administration. Change in plasma glucose excursion was calculated by subtracting baseline value from Week 24 value. Missing data was imputed using LOCF. On-treatment period for this efficacy variable was defined as the time from the first dose of study drug till before the introduction of rescue medication and up to the date of last injection of IMP.
Change in Average 7-Point Self-Monitored Plasma Glucose (SMPG) Profiles From Baseline to Week 24
Participants recorded a 7-point plasma glucose profile measured before and 2-hours after each meal and at bedtime, over a single day, once in a week before baseline, before visit Week 12 and before visit Week 24 and the average value across the profiles performed in the week before a visit for the 7-time points was calculated. Change in average 7-point SMPG was calculated by subtracting baseline value from Week 24 value. Missing data was imputed using LOCF. On-treatment period for this efficacy variable was defined as the time from the first dose of study drug till before the introduction of rescue medication and up to the date of last injection of IMP.
Change in Body Weight From Baseline to Week 24
Change in body weight was calculated by subtracting baseline value from Week 24 value. Missing data was imputed using LOCF. On-treatment period for this efficacy variable was defined as the time from the first dose of study drug till before the introduction of rescue medication and up to 3 days after the last injection of IMP.
Average Daily Insulin Glargine Dose at Week 24
Missing data was imputed using LOCF. On-treatment period for this efficacy variable was defined as the time from the first dose of study drug till before the introduction of rescue medication and up to the date of last injection of IMP.
Change in FPG From Baseline to Week 24
Change in FPG was calculated by subtracting baseline value from Week 24 value. Missing data was imputed using LOCF. On-treatment period for this efficacy variable was defined as the time from the first dose of study drug till before the introduction of rescue medication and up to 1 day after the last injection of IMP.
Percentage of Participants Requiring Rescue Therapy During 24-week Treatment Period
Routine fasting SMPG and central laboratory FPG (and HbA1c after Week 12) values were used to determine the requirement of rescue medication. If fasting SMPG value exceed the specified limit for 3 consecutive days, the central laboratory FPG (and HbA1c after Week 12) were performed. Threshold values from Week 8 to Week 12: fasting SMPG/FPG >240 mg/dL (13.3 mmol/L), and from Week 12 to Week 30: fasting SMPG/FPG >200 mg/dL (11.1 mmol/L) or HbA1c >8%.
Percentage of Participants With HbA1c ≤6.5 % or <7.0 % at Week 24
On-treatment period for this efficacy variable was defined as the time from the first dose of study drug till before the introduction of rescue medication and up to 14 days after the last injection of IMP.
Change in 30-minute and 1-hour PPG From Baseline to Week 24
The 30 minute and 1-hour PPG test measured blood glucose 30 minutes and 1-hour after eating a standardized meal. Change in PPG was calculated by subtracting baseline value from Week 24 value. Missing data was imputed using LOCF. On-treatment period for this efficacy variable was defined as the time from the first dose of study drug till before the introduction of rescue medication and up to the date of last injection of IMP.
Change in 30 Minute and 1-hour Plasma Glucose Excursion From Baseline to Week 24
30-minute and 1-hour plasma glucose excursion = 30-minute and 1-hour PPG minus plasma glucose value obtained 30 minutes prior to the start of the meal and before IMP administration. Change in plasma glucose excursion was calculated by subtracting baseline value from Week 24 value. Missing data was imputed using LOCF. On-treatment period for this efficacy variable was defined as the time from the first dose of study drug till before the introduction of rescue medication and up to the date of last injection of IMP.
Percentage of Participants Reaching HbA1c <7% at Week 24 With no Documented Symptomatic Hypoglycemia During 24-week Treatment Period
Documented symptomatic hypoglycemia was an event during which typical symptoms of hypoglycemia were accompanied by a measured plasma glucose concentration of ≤70 mg/dL (3.9 mmol/L). Participants without any post-baseline on-treatment value for HbA1c were counted as non-responders if they experienced at least one documented symptomatic hypoglycemia before the introduction of rescue medication and up to 1 day after the last injection of IMP. Otherwise, they were counted as missing data. On-treatment period for this efficacy variable was defined as the time from the first dose of study drug till before the introduction of rescue medication and up to 14 days after the last injection of IMP.
Percentage of Participants Reaching HbA1c <7% With no Body Weight Gain at Week 24
Participants without any post-baseline on-treatment values (for HbA1c and body weight) that were no more than 30 days apart were counted as non-responders if at least one of the components (for HbA1c and body weight) was available and showed non-response. Otherwise, they were counted as missing data.
Percentage of Participants With Documented Symptomatic and Severe Symptomatic Hypoglycemia
Documented symptomatic hypoglycemia was an event during which typical symptoms of hypoglycemia were accompanied by a measured plasma glucose concentration of ≤70 mg/dL (3.9 mmol/L).Severe symptomatic hypoglycemia was an event requiring assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. These episodes were associated with sufficient neuroglycopenia to induce seizure, unconsciousness or coma. All episodes in which neurological impairment was severe enough to prevent self-treatment and which were thought to place participants at risk for injury to themselves or others.

Full Information

First Posted
November 4, 2011
Last Updated
December 16, 2016
Sponsor
Sanofi
search

1. Study Identification

Unique Protocol Identification Number
NCT01476475
Brief Title
Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Combination Versus Insulin Glargine Alone on Top of Metformin in Type 2 Diabetic Patients
Official Title
A Randomized, 24-week, Open-label, 2-arm Parallel-group, Multicenter Study Comparing the Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine on Top of Metformin in Type 2 Diabetic Patients
Study Type
Interventional

2. Study Status

Record Verification Date
December 2016
Overall Recruitment Status
Completed
Study Start Date
November 2011 (undefined)
Primary Completion Date
December 2012 (Actual)
Study Completion Date
December 2012 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Sanofi

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Primary Objective: The purpose of this study was to compare insulin glargine/ lixisenatide fixed ratio combination (FRC) versus insulin glargine on glycemic control over 24 weeks, as evaluated by glycosylated hemoglobin (HbA1c) reduction in type 2 diabetic participants treated with metformin. Secondary Objectives: To compare insulin glargine/lixisenatide FRC versus insulin glargine over 24 weeks on: Glycemic control in relation to a meal as evaluated by post-prandial plasma glucose and glucose excursions during a standardized meal test; Percentage of participants reaching HbA1c <7% or ≤6.5%; 7-point Self-Monitored Plasma Glucose (SMPG) profile; Body weight; Insulin glargine dose Fasting Plasma Glucose (FPG); Percentage of participants requiring rescue therapy during the 24-week open label treatment period; To assess safety and tolerability of insulin glargine/lixisenatide FRC.
Detailed Description
Approximately 27 weeks including a 24-week treatment period.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes Mellitus

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
323 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Insulin glargine/Lixisenatide Fixed Ratio Combination (FRC)
Arm Type
Experimental
Arm Description
FRC injected once daily (QD) for 24 weeks. Dose individually adjusted.
Arm Title
Insulin glargine
Arm Type
Active Comparator
Arm Description
Insulin glargine QD for 24 weeks. Dose individually adjusted.
Intervention Type
Drug
Intervention Name(s)
Insulin glargine /lixisenatide Fixed Ratio Combination
Other Intervention Name(s)
(HOE901/AVE0010)
Intervention Description
FRC was self-administered by subcutaneous (SC) injection within 1 hour before breakfast using pen-type injector (Tactipen®): 100 U/ml insulin glargine and 50 mcg Lixisenatide (ratio of 2 U/1 mcg). The initial dose was 10 U/5 mcg and then dose was adjusted weekly to reach and maintain fasting self-monitored plasma glucose (SMPG) of 80 mg/dL to 100 mg/dL (4.4 mmol/L to 5.6 mmol/L.
Intervention Type
Drug
Intervention Name(s)
Insulin glargine
Other Intervention Name(s)
Lantus
Intervention Description
Insulin glargine (100 U/ml) was self-administered by SC injection before breakfast using pen-type injector (Lantus® Solostar®). The initial daily dose of insulin glargine was 10 U and then dose was adjusted weekly to reach and maintain fasting SMPG of 80 mg/dL to 100 mg/dL (4.4 mmol/L to 5.6 mmol/L).
Intervention Type
Drug
Intervention Name(s)
Metformin (Background drug)
Intervention Description
Pharmaceutical form: Tablet; Route of administration: oral administration. To be kept at stable dose (≥1.5 g/day) throughout the study.
Primary Outcome Measure Information:
Title
Change in HbA1c From Baseline to Week 24
Description
Change in HbA1c was calculated by subtracting baseline value from Week 24 value. Missing data was imputed using last observation carried forward (LOCF). On-treatment period for this efficacy variable was defined as the time from the first dose of study drug till before the introduction of rescue medication and up to 14 days after the last injection of investigational medicinal product (IMP).
Time Frame
Baseline, Week 24
Secondary Outcome Measure Information:
Title
Change in 2-hour Postprandial Plasma Glucose (PPG) From Baseline to Week 24
Description
The 2-hour PPG test measured blood glucose 2 hours after eating a standardized meal. Change in PPG was calculated by subtracting baseline value from Week 24 value. Missing data was imputed using LOCF. On-treatment period for this efficacy variable was defined as the time from the first dose of study drug till before the introduction of rescue medication and up to the date of last injection of IMP.
Time Frame
Baseline, Week 24
Title
Change in 2-hour Plasma Glucose Excursion From Baseline to Week 24
Description
2-hour plasma glucose excursion = 2-hour PPG minus plasma glucose value obtained 30 minutes prior to the start of the meal and before IMP administration. Change in plasma glucose excursion was calculated by subtracting baseline value from Week 24 value. Missing data was imputed using LOCF. On-treatment period for this efficacy variable was defined as the time from the first dose of study drug till before the introduction of rescue medication and up to the date of last injection of IMP.
Time Frame
Baseline, Week 24
Title
Change in Average 7-Point Self-Monitored Plasma Glucose (SMPG) Profiles From Baseline to Week 24
Description
Participants recorded a 7-point plasma glucose profile measured before and 2-hours after each meal and at bedtime, over a single day, once in a week before baseline, before visit Week 12 and before visit Week 24 and the average value across the profiles performed in the week before a visit for the 7-time points was calculated. Change in average 7-point SMPG was calculated by subtracting baseline value from Week 24 value. Missing data was imputed using LOCF. On-treatment period for this efficacy variable was defined as the time from the first dose of study drug till before the introduction of rescue medication and up to the date of last injection of IMP.
Time Frame
Baseline, Week 24
Title
Change in Body Weight From Baseline to Week 24
Description
Change in body weight was calculated by subtracting baseline value from Week 24 value. Missing data was imputed using LOCF. On-treatment period for this efficacy variable was defined as the time from the first dose of study drug till before the introduction of rescue medication and up to 3 days after the last injection of IMP.
Time Frame
Baseline, Week 24
Title
Average Daily Insulin Glargine Dose at Week 24
Description
Missing data was imputed using LOCF. On-treatment period for this efficacy variable was defined as the time from the first dose of study drug till before the introduction of rescue medication and up to the date of last injection of IMP.
Time Frame
Week 24
Title
Change in FPG From Baseline to Week 24
Description
Change in FPG was calculated by subtracting baseline value from Week 24 value. Missing data was imputed using LOCF. On-treatment period for this efficacy variable was defined as the time from the first dose of study drug till before the introduction of rescue medication and up to 1 day after the last injection of IMP.
Time Frame
Baseline, Week 24
Title
Percentage of Participants Requiring Rescue Therapy During 24-week Treatment Period
Description
Routine fasting SMPG and central laboratory FPG (and HbA1c after Week 12) values were used to determine the requirement of rescue medication. If fasting SMPG value exceed the specified limit for 3 consecutive days, the central laboratory FPG (and HbA1c after Week 12) were performed. Threshold values from Week 8 to Week 12: fasting SMPG/FPG >240 mg/dL (13.3 mmol/L), and from Week 12 to Week 30: fasting SMPG/FPG >200 mg/dL (11.1 mmol/L) or HbA1c >8%.
Time Frame
Baseline up to Week 24
Title
Percentage of Participants With HbA1c ≤6.5 % or <7.0 % at Week 24
Description
On-treatment period for this efficacy variable was defined as the time from the first dose of study drug till before the introduction of rescue medication and up to 14 days after the last injection of IMP.
Time Frame
Week 24
Title
Change in 30-minute and 1-hour PPG From Baseline to Week 24
Description
The 30 minute and 1-hour PPG test measured blood glucose 30 minutes and 1-hour after eating a standardized meal. Change in PPG was calculated by subtracting baseline value from Week 24 value. Missing data was imputed using LOCF. On-treatment period for this efficacy variable was defined as the time from the first dose of study drug till before the introduction of rescue medication and up to the date of last injection of IMP.
Time Frame
Baseline, Week 24
Title
Change in 30 Minute and 1-hour Plasma Glucose Excursion From Baseline to Week 24
Description
30-minute and 1-hour plasma glucose excursion = 30-minute and 1-hour PPG minus plasma glucose value obtained 30 minutes prior to the start of the meal and before IMP administration. Change in plasma glucose excursion was calculated by subtracting baseline value from Week 24 value. Missing data was imputed using LOCF. On-treatment period for this efficacy variable was defined as the time from the first dose of study drug till before the introduction of rescue medication and up to the date of last injection of IMP.
Time Frame
Baseline, Week 24
Title
Percentage of Participants Reaching HbA1c <7% at Week 24 With no Documented Symptomatic Hypoglycemia During 24-week Treatment Period
Description
Documented symptomatic hypoglycemia was an event during which typical symptoms of hypoglycemia were accompanied by a measured plasma glucose concentration of ≤70 mg/dL (3.9 mmol/L). Participants without any post-baseline on-treatment value for HbA1c were counted as non-responders if they experienced at least one documented symptomatic hypoglycemia before the introduction of rescue medication and up to 1 day after the last injection of IMP. Otherwise, they were counted as missing data. On-treatment period for this efficacy variable was defined as the time from the first dose of study drug till before the introduction of rescue medication and up to 14 days after the last injection of IMP.
Time Frame
Baseline up to Week 24
Title
Percentage of Participants Reaching HbA1c <7% With no Body Weight Gain at Week 24
Description
Participants without any post-baseline on-treatment values (for HbA1c and body weight) that were no more than 30 days apart were counted as non-responders if at least one of the components (for HbA1c and body weight) was available and showed non-response. Otherwise, they were counted as missing data.
Time Frame
Week 24
Title
Percentage of Participants With Documented Symptomatic and Severe Symptomatic Hypoglycemia
Description
Documented symptomatic hypoglycemia was an event during which typical symptoms of hypoglycemia were accompanied by a measured plasma glucose concentration of ≤70 mg/dL (3.9 mmol/L).Severe symptomatic hypoglycemia was an event requiring assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. These episodes were associated with sufficient neuroglycopenia to induce seizure, unconsciousness or coma. All episodes in which neurological impairment was severe enough to prevent self-treatment and which were thought to place participants at risk for injury to themselves or others.
Time Frame
First dose of study drug up to 3 days after the last dose administration (maximum of 219 days)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria: Participants with type 2 diabetes mellitus diagnosed for at least 1 year. Metformin treatment at a stable dose of at least 1.5 g/day for at least 3 months prior to screening. Exclusion criteria: Age < legal age of adulthood (18 years). Screening HbA1c <7% or >10%. Screening FPG >250 mg/dL (>13.9 mmol/L). Pregnancy or lactation, women of childbearing potential with no effective contraceptive method. Type 1 diabetes mellitus. Treatment with glucose-lowering agent(s) other than metformin in a period of 3 months prior to screening. Use of insulin within the last 6 months. Previous use of insulin, except for episode(s) of short-term treatment (≤15 consecutive days) due to intercurrent illness. Amylase and/or lipase >3 times the upper limit of the normal laboratory range (ULN) at screening. Calcitonin ≥20 pg/ml (5.9 pmol/l) at screening. Alanine Transferase (ALT) >3 ULN at screening. History of unexplained pancreatitis, chronic pancreatitis, pancreatectomy. Personal or immediate family history of medullary thyroid cancer (MTC) or genetic conditions that predisposes to MTC (e.g. multiple endocrine neoplasia syndromes). Uncontrolled or inadequately controlled hypertension at the time of screening with a resting supine systolic or diastolic blood pressure >180 mmHg or >110 mmHg, respectively. Within the last 6 months prior to screening: history of heart failure requiring hospitalization, myocardial infarction, or stroke. Planned coronary, carotid or peripheral artery revascularisation procedures. Body Mass Index (BMI) ≤20 or >40 kg/m^2. Any previous treatment with lixisenatide The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Clinical Sciences & Operations
Organizational Affiliation
Sanofi
Official's Role
Study Director
Facility Information:
Facility Name
Investigational Site Number 840408
City
Little Rock
State/Province
Arkansas
ZIP/Postal Code
72205
Country
United States
Facility Name
Investigational Site Number 840412
City
Paramount
State/Province
California
ZIP/Postal Code
90723
Country
United States
Facility Name
Investigational Site Number 840401
City
Larenceville
State/Province
Georgia
ZIP/Postal Code
30045
Country
United States
Facility Name
Investigational Site Number 840417
City
Roswell
State/Province
Georgia
ZIP/Postal Code
30076
Country
United States
Facility Name
Investigational Site Number 840403
City
Lexington
State/Province
Kentucky
ZIP/Postal Code
40504
Country
United States
Facility Name
Investigational Site Number 840404
City
Hyattsville
State/Province
Maryland
ZIP/Postal Code
20782
Country
United States
Facility Name
Investigational Site Number 840405
City
Rockville
State/Province
Maryland
ZIP/Postal Code
20852
Country
United States
Facility Name
Investigational Site Number 840411
City
Las Vegas
State/Province
Nevada
ZIP/Postal Code
89148
Country
United States
Facility Name
Investigational Site Number 840415
City
West Seneca
State/Province
New York
ZIP/Postal Code
14224
Country
United States
Facility Name
Investigational Site Number 840402
City
Norman
State/Province
Oklahoma
ZIP/Postal Code
73069
Country
United States
Facility Name
Investigational Site Number 840407
City
Medford
State/Province
Oregon
ZIP/Postal Code
97504
Country
United States
Facility Name
Investigational Site Number 840413
City
Durham
State/Province
Pennsylvania
ZIP/Postal Code
27713
Country
United States
Facility Name
Investigational Site Number 840410
City
Dallas
State/Province
Texas
ZIP/Postal Code
75230
Country
United States
Facility Name
Investigational Site Number 840414
City
Renton
State/Province
Washington
ZIP/Postal Code
98055
Country
United States
Facility Name
Investigational Site Number 152404
City
Santiago
ZIP/Postal Code
7500347
Country
Chile
Facility Name
Investigational Site Number 152405
City
Santiago
ZIP/Postal Code
7500347
Country
Chile
Facility Name
Investigational Site Number 152403
City
Santiago
ZIP/Postal Code
7500710
Country
Chile
Facility Name
Investigational Site Number 152401
City
Santiago
ZIP/Postal Code
7980378
Country
Chile
Facility Name
Investigational Site Number 152402
City
Santiago
ZIP/Postal Code
8320000
Country
Chile
Facility Name
Investigational Site Number 203403
City
Novy Jicin
ZIP/Postal Code
74101
Country
Czech Republic
Facility Name
Investigational Site Number 203401
City
Plzen
ZIP/Postal Code
32600
Country
Czech Republic
Facility Name
Investigational Site Number 203402
City
Praha 2
ZIP/Postal Code
12808
Country
Czech Republic
Facility Name
Investigational Site Number 203405
City
Praha 8
ZIP/Postal Code
18100
Country
Czech Republic
Facility Name
Investigational Site Number 208401
City
København Nv
ZIP/Postal Code
2400
Country
Denmark
Facility Name
Investigational Site Number 208404
City
Køge
ZIP/Postal Code
4600
Country
Denmark
Facility Name
Investigational Site Number 208402
City
Slagelse
ZIP/Postal Code
4200
Country
Denmark
Facility Name
Investigational Site Number 208403
City
Svendborg
ZIP/Postal Code
5700
Country
Denmark
Facility Name
Investigational Site Number 250402
City
Narbonne
ZIP/Postal Code
11018
Country
France
Facility Name
Investigational Site Number 250404
City
Poitiers Cedex
ZIP/Postal Code
86021
Country
France
Facility Name
Investigational Site Number 250401
City
Vandoeuvre Les Nancy
ZIP/Postal Code
54511
Country
France
Facility Name
Investigational Site Number 276401
City
Dresden
ZIP/Postal Code
01307
Country
Germany
Facility Name
Investigational Site Number 276402
City
Ludwigshafen
ZIP/Postal Code
67059
Country
Germany
Facility Name
Investigational Site Number 276403
City
Oberhausen
ZIP/Postal Code
46045
Country
Germany
Facility Name
Investigational Site Number 348401
City
Balatonfüred
ZIP/Postal Code
8230
Country
Hungary
Facility Name
Investigational Site Number 348405
City
Budapest
ZIP/Postal Code
1041
Country
Hungary
Facility Name
Investigational Site Number 348406
City
Budapest
ZIP/Postal Code
1212
Country
Hungary
Facility Name
Investigational Site Number 348404
City
Debrecen
ZIP/Postal Code
4043
Country
Hungary
Facility Name
Investigational Site Number 348402
City
Szeged
ZIP/Postal Code
6720
Country
Hungary
Facility Name
Investigational Site Number 348403
City
Szeged
ZIP/Postal Code
6722
Country
Hungary
Facility Name
Investigational Site Number 440401
City
Kaunas
ZIP/Postal Code
LT-49456
Country
Lithuania
Facility Name
Investigational Site Number 440402
City
Kaunas
ZIP/Postal Code
LT-51270
Country
Lithuania
Facility Name
Investigational Site Number 440403
City
Kedainiai
ZIP/Postal Code
LT-57164
Country
Lithuania
Facility Name
Investigational Site Number 440404
City
Klaipeda
ZIP/Postal Code
LT-92304
Country
Lithuania
Facility Name
Investigational Site Number 484404
City
Acapulco
ZIP/Postal Code
39670
Country
Mexico
Facility Name
Investigational Site Number 484401
City
Cuernavaca
ZIP/Postal Code
62250
Country
Mexico
Facility Name
Investigational Site Number 484405
City
Durango
ZIP/Postal Code
34270
Country
Mexico
Facility Name
Investigational Site Number 484402
City
Guadalajara
ZIP/Postal Code
44210
Country
Mexico
Facility Name
Investigational Site Number 484403
City
Guadalajara
ZIP/Postal Code
44656
Country
Mexico
Facility Name
Investigational Site Number 616405
City
Bialystok
ZIP/Postal Code
15-435
Country
Poland
Facility Name
Investigational Site Number 616406
City
Gdansk
ZIP/Postal Code
80-847
Country
Poland
Facility Name
Investigational Site Number 616403
City
Krakow
ZIP/Postal Code
31-548
Country
Poland
Facility Name
Investigational Site Number 616407
City
Lodz
ZIP/Postal Code
94-074
Country
Poland
Facility Name
Investigational Site Number 616404
City
Pulawy
ZIP/Postal Code
24-100
Country
Poland
Facility Name
Investigational Site Number 616402
City
Szczecin
ZIP/Postal Code
70-506
Country
Poland
Facility Name
Investigational Site Number 616401
City
Warszawa
ZIP/Postal Code
02-507
Country
Poland
Facility Name
Investigational Site Number 642402
City
Brasov
ZIP/Postal Code
500365
Country
Romania
Facility Name
Investigational Site Number 642403
City
Bucuresti
ZIP/Postal Code
020475
Country
Romania
Facility Name
Investigational Site Number 642405
City
Iasi
ZIP/Postal Code
700547
Country
Romania
Facility Name
Investigational Site Number 642401
City
Oradea
ZIP/Postal Code
410169
Country
Romania
Facility Name
Investigational Site Number 642406
City
Targu Mures
ZIP/Postal Code
540142
Country
Romania
Facility Name
Investigational Site Number 642404
City
Timisoara
ZIP/Postal Code
300133
Country
Romania
Facility Name
Investigational Site Number 703402
City
Bratislava
ZIP/Postal Code
85101
Country
Slovakia
Facility Name
Investigational Site Number 703403
City
Kosice
ZIP/Postal Code
04001
Country
Slovakia
Facility Name
Investigational Site Number 703406
City
Kosice
ZIP/Postal Code
04013
Country
Slovakia
Facility Name
Investigational Site Number 703404
City
Moldava Nad Bodvou
ZIP/Postal Code
04525
Country
Slovakia
Facility Name
Investigational Site Number 703405
City
Nitra
ZIP/Postal Code
94911
Country
Slovakia
Facility Name
Investigational Site Number 703401
City
Zilina
ZIP/Postal Code
01001
Country
Slovakia
Facility Name
Investigational Site Number 752402
City
Skellefteå
ZIP/Postal Code
931 32
Country
Sweden
Facility Name
Investigational Site Number 752401
City
Stockholm
ZIP/Postal Code
171 76
Country
Sweden
Facility Name
Investigational Site Number 752403
City
Växjö
ZIP/Postal Code
351 85
Country
Sweden

12. IPD Sharing Statement

Citations:
PubMed Identifier
27284114
Citation
Rosenstock J, Diamant M, Aroda VR, Silvestre L, Souhami E, Zhou T, Perfetti R, Fonseca V; LixiLan PoC Study Group. Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Lixisenatide and Insulin Glargine, Versus Insulin Glargine in Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy: The LixiLan Proof-of-Concept Randomized Trial. Diabetes Care. 2016 Sep;39(9):1579-86. doi: 10.2337/dc16-0046. Epub 2016 Jun 9.
Results Reference
result
Links:
URL
https://www.ncbi.nlm.nih.gov/pubmed/?term=27284114
Description
Related Info

Learn more about this trial

Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Combination Versus Insulin Glargine Alone on Top of Metformin in Type 2 Diabetic Patients

We'll reach out to this number within 24 hrs